Recruiting

Omega-3 Monoglycerides

Sponsor:

SCF Pharma

Code:

NCT05161702

Conditions

Resolution of Inflammation

Reduction of Cell Proliferation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

MAG-SPM treatment on isolated PBMC cells

Isolated PBMC cells without treatment.

Study Details

Brief summary:

The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride omega-3 fatty acids on the resolution of inflammation.

Conditions

Resolution of Inflammation

Reduction of Cell Proliferation

Study ID

NCT05161702

Start date

Mar 12, 2019

Status verified date

Apr, 2026

Completion date

Jan 1, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Participant aged of at least 18 years old.

Exclusion Criteria:

  • Participant who use omega-3 supplements and / or anti-inflammatory medication such as, but not limited to - Aspirin, Ibuprofen (Motrin, Advil), Celecoxib (Celebrex), diclofenac (Cambia, Cataflam, Voltaren ) within 7 days of day 1 of the study.

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Interventions

MAG-SPM treatment on isolated PBMC cells

Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.

Isolated PBMC cells without treatment.

Cells are isolated form the participant's blood donation (4x 10mL k2EDTA tubes per participant) and maintained in culture with LPS, a pro-inflammatory and pro-proliferative agent. Then, PBMC are separated in two, one half treated with MAG-SPM and the other half remains with LPS only. Proliferative activities are measured and compared in both cell dish.

Primary outcome measure

  • Number of PBMC cells count [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Samuel Fortin, PhD

418-750-8590sfortin@scfpharma.com

Anne-Julie Landry, M.Sc

ajlandry@scfpharma.com

Locations

SCF Pharma

Recruiting

Rimouski, Quebec, Canada, G0K 1P0

Contacts

Samuel Fortin, PhD

418-750-8590sfortin@scfpharma.com

More Information

Sponsor

SCF Pharma

Last update posted

Apr 17, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by SCF Pharma on 2026-04-17.